Esomeprazole potassium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414081

CAS#: 161796-84-5 (K)

Description: Esomeprazole potassium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.

Chemical Structure

img
Esomeprazole potassium
CAS# 161796-84-5 (K)
Instruction

Theoretical Analysis

MedKoo Cat#: 414081
Name: Esomeprazole potassium
CAS#: 161796-84-5 (K)
Chemical Formula: C17H18KN3O3S
Exact Mass: 0.00
Molecular Weight: 383.510
Elemental Analysis: C, 53.24; H, 4.73; K, 10.19; N, 10.96; O, 12.52; S, 8.36

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 161796-78-7(sodium)   119141-88-7(free)   161973-10-0 (magnesium)   217087-09-7 (magnesium hydrate)   161796-84-5 (potassium)   914613-86-8 (strontium anhydrous)  

Synonym: Esomeprazole potassium

IUPAC/Chemical Name: 1H-Benzimidazole, 6-methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-, potassium salt (1:1)

InChi Key: FOFFPEFVSRGLOZ-JIDHJSLPSA-N

InChi Code: InChI=1S/C17H18N3O3S.K/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1/t24-;/m0./s1

SMILES Code: O=[S@](C1=NC2=CC=C(OC)C=C2[N-]1)CC3=NC=C(C)C(OC)=C3C.[K+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 383.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dermyshi E, Mackie C, Kigozi P, Schoonakker B, Dorling J. Antacid therapy for

gastroesophageal reflux in preterm infants: a systematic review. BMJ Paediatr Open. 2018 Jul 9;2(1):e000287. doi: 10.1136/bmjpo-2018-000287. eCollection 2018.

PubMed PMID: 30019019; PubMed Central PMCID: PMC6045735.

2: Al-Ghobashy MA, Kamal SM, El-Sayed GM, Attia AK, Nagy M, ElZeiny A, Elrakaiby

MT, Nooh MM, Abbassi M, Aziz RK. Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS/MS: A

key step towards personalized therapeutics. J Chromatogr B Analyt Technol Biomed

Life Sci. 2018 Aug 15;1092:489-498. doi: 10.1016/j.jchromb.2018.06.043. Epub 2018 Jun 27. PubMed PMID: 30008305.

3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK501284/ PubMed PMID: 30000343.

4: Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Efficacies of Genotypic Resistance-guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology. 2018 Jun 28. pii: S0016-5085(18)34689-4. doi: 10.1053/j.gastro.2018.06.047. [Epub ahead of print] PubMed PMID: 29964036.

5: Lovell DJ, Dare JA, Francis-Sedlak M, Ball J, LaMoreaux BD, Von Scheven E, Reinhardt A, Jerath R, Alpan O, Gupta R, Goldsmith D, Zeft A, Naddaf H, Gottlieb

B, Jung L, Holt RJ. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.

Pediatr Rheumatol Online J. 2018 Jun 26;16(1):41. doi: 10.1186/s12969-018-0260-y. PubMed PMID: 29941047; PubMed Central PMCID: PMC6019234.

6: Bong YK, Song S, Nazor J, Vogel M, Widegren M, Smith D, Collier SJ, Wilson R,

Palanivel SM, Narayanaswamy K, Mijts B, Clay MD, Fong R, Colbeck J, Appaswami A,

Muley S, Zhu J, Zhang X, Liang J, Entwistle D. Baeyer-Villiger Monooxygenase-Mediated Synthesis of Esomeprazole As an Alternative for Kagan Sulfoxidation. J Org Chem. 2018 Jun 22. doi: 10.1021/acs.joc.8b00468. [Epub ahead of print] PubMed PMID: 29932340.

7: Gan HY, Peng TL, Huang YM, Su KH, Zhao LL, Yao LY, Yang RJ. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial. Sci Rep. 2018 Jun 13;8(1):9045. doi: 10.1038/s41598-018-27482-2. PubMed PMID: 29899426; PubMed Central PMCID: PMC5998071.

8: Asempa TE, Avery LM, Kidd JM, Kuti JL, Nicolau DP. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health Syst Pharm. 2018 Jul 15;75(14):1048-1056. doi: 10.2146/ajhp170839. Epub 2018 Jun 12. PubMed PMID: 29895521.

9: Pauwels A, Broers C, Vanuytsel T, Pardon N, Cocca S, Roman S, Zerbib F, Tack J, Farré R. A reduced esophageal epithelial integrity in a subgroup of healthy individuals increases with proton pump inhibitor therapy. United European Gastroenterol J. 2018 May;6(4):511-518. doi: 10.1177/2050640617749115. Epub 2017

Dec 17. PubMed PMID: 29881606; PubMed Central PMCID: PMC5987278.

10: Chen L, He J, Wang L, Ge Q, Chu H, Chen Y, Chen X, Long Y, Deng Y, He H, Li A, Chen S. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med. 2018 Jun 6. doi: 10.1007/s10238-018-0510-9. [Epub ahead of print] PubMed PMID: 29876770.

11: Sunwoo J, Oh J, Moon SJ, Ji SC, Lee SH, Yu KS, Kim HS, Lee A, Jang IJ. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel

potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. doi: 10.1111/apt.14818. Epub 2018 Jun 4. PubMed PMID: 29863280.

12: Liou JM, Chen CC, Fang YJ, Chen PY, Chang CY, Chou CK, Chen MJ, Tseng CH, Lee JY, Yang TH, Chiu MC, Yu JJ, Kuo CC, Luo JC, Hsu WF, Hu WH, Tsai MH, Lin JT, Shun CT, Twu G, Lee YC, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial. J Antimicrob Chemother. 2018 May 29. doi: 10.1093/jac/dky183. [Epub ahead of print] PubMed PMID: 29846605.

13: Zhuang XY, Yang HZ, Wang HG, Li CW. [Clinical observation of Weisu granules in treating laryngopharyngeal reflux]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018 Mar;32(5):369-371. doi: 10.13201/j.issn.1001-1781.2018.05.012. Chinese. PubMed PMID: 29798296.

14: Lei L, Yang H, Zhao Y, Zhang XS, Zou J, Ren J, Zheng YT, Ren JJ. [A comparative study of therapy effects between esomeprazole plus mosapride citrate

and botulinum toxin injection on vocal process granuloma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jul 5;31(13):1006-1009. doi: 10.13201/j.issn.1001-1781.2017.13.009. Chinese. PubMed PMID: 29798164.

15: Boltin D, Zvidi I, Raskin M, Kayless H, Schmilovitz-Weiss H, Gingold-Belfer R, Niv Y, Dickman R. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. Dig Dis. 2018;36(4):257-263. doi: 10.1159/000489557. Epub 2018 May 23. PubMed PMID: 29791895.

16: Peura DA, Le Moigne A, Wassel H, Pollack C. Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials. BMC Gastroenterol. 2018 May

22;18(1):69. doi: 10.1186/s12876-018-0790-2. PubMed PMID: 29788903; PubMed Central PMCID: PMC5964662.

17: Hsin IF, Hsu SJ, Chuang CL, Huo TI, Huang HC, Lee FY, Ho HL, Chang SY, Lee SD. The effects of proton pump inhibitor on hepatic vascular responsiveness and hemodynamics in cirrhotic rats. J Chin Med Assoc. 2018 Jul;81(7):585-592. doi: 10.1016/j.jcma.2018.01.011. Epub 2018 May 18. PubMed PMID: 29780000.

18: Shafik AN, Khattab MA, Osman AH. Magnesium sulfate versus esomeprazole impact on the neonates of preeclamptic rats. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:236-242. doi: 10.1016/j.ejogrb.2018.05.004. Epub 2018 May 8. PubMed PMID: 29758543.

19: Leung WK, But DY, Wong SY, Tong TS, Liu KS, Cheung KS, Tsang SH, Chok KS, Poon RT, Hung IF. Prevention of post-sphincterotomy bleeding by proton pump inhibitor: A randomized controlled trial. J Dig Dis. 2018 Jun;19(6):369-376. doi: 10.1111/1751-2980.12604. Epub 2018 May 24. PubMed PMID: 29722146.

20: Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018 Jun;23(3):e12485. doi: 10.1111/hel.12485. Epub 2018 Apr 25. PubMed PMID: 29696736.